Investor Relations

Orexo's share is listed on NasdaqOMX Stockholm, Sweden (ORX), and is available as American Depository Receipts on OTCQX market in the US (OXROY).

Share price

Name
0.00
0 SEK (0%)
HH:MM CET • 20YY-MM-DD
ESG sustainability investing

Orexo has established a social financing framework

Read more

Presentation of Q4 2023 incl. the Full Year Report

Click the link to watch the presentation on February 8. 

Extraordinary General Meeting on October 26

Read the protocol from the EGM under Corporate Governance - EGM

Latest CEO Comments

FEBRUARY 8, 2024

"Strong recovery in financial results and FDA initiated the review of OX124"

Read the latest CEO comments from Nikolaj Sørensen

Key financial figures

Group net revenue

639 MSEK
Last Twelve Months, Q123-Q423

Group EBITDA

-33 MSEK
Last Twelve Months, Q123-Q423

US Pharma segment EBIT

283 MSEK
Last Twelve Months, Q123-Q423

Cash position

171 MSEK
Q423
IR-Contact